Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2022

Shareholders' Equity

Summary of comprehensive income (loss)

The following is a summary of comprehensive income (in millions):

	Three Months Ended March 31,
	2022			2021
Consolidated net income	$	62.1		$	57.8
Foreign currency translation adjustments		(30.5	)		(68.0	)
Derivatives designated as hedging instruments, net of tax		21.1			48.5
Pension liability adjustments, net of tax		0.5			3.3
Net comprehensive income		53.2			41.6
Less: Comprehensive income attributable to noncontrolling interests		0.2			0.9
Less: Comprehensive loss attributable to redeemable noncontrolling interests		(0.2	)		—
Comprehensive income attributable to Bruker Corporation	$	53.2		$	40.7

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income, net of tax (in millions):

	Foreign Currency Translation			Derivatives Designated as Hedging Instruments			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021	$	63.1		$	(40.1	)	$	(31.2	)	$	(8.2	)
Other comprehensive (loss) income before    reclassifications, net of tax		(30.5	)		21.1			0.2			(9.2	)
Realized gain on amounts reclassified from other    comprehensive income, net of tax		—			—			0.3			0.3
Net current period other comprehensive (loss) income		(30.5	)		21.1			0.5			(8.9	)
Balance at March 31, 2022	$	32.6		$	(19.0	)	$	(30.7	)	$	(17.1	)

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

	Three Months Ended March 31,
	2022		2021
Costs of product revenue	$	0.6	$	0.5
Selling, general and administrative		2.6		2.4
Research and development		0.6		0.5
Total stock-based compensation expense	$	3.8	$	3.4